These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 38736182)

  • 1. Evaluating Oral Probiotic Supplements as Complementary Treatment in Advanced Lung Cancer Patients Receiving ICIs: A Prospective Real-World Study.
    Tong L; Wan Y; Shi X; Liu X; Liu Z; Li Y; Zhang Y; Luo D; Zhu J
    Cancer Control; 2024; 31():10732748241253959. PubMed ID: 38736182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construction of a prognostic model for extensive-stage small cell lung cancer patients undergoing immune therapy in northernmost China and prediction of treatment efficacy based on response status at different time points.
    Dang J; Xu G; Guo G; Zhang H; Shang L
    J Cancer Res Clin Oncol; 2024 May; 150(5):255. PubMed ID: 38750370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of immune checkpoint inhibitors at different treatment time periods on prognosis of patients with extensive-stage small-cell lung cancer.
    Mi S; Yang Y; Liu X; Tang S; Liang N; Sun J; Liu C; Ren Q; Lu J; Hu P; Zhang J
    Clin Transl Oncol; 2024 Sep; 26(9):2339-2350. PubMed ID: 38598001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Women patients with small-cell lung cancer using immunotherapy in a real-world cohort achieved long-term survival.
    He Y; Kong L; Ji X; Zhuo M; An T; Jia B; Chi Y; Wang J; Zhao J; Li J; Yang X; Chen H; Zhai X; Tai Y; Ding L; Wang Z; Wang Y
    Thorac Cancer; 2024 Aug; 15(23):1727-1738. PubMed ID: 38923348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
    Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
    Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The landscape of immune checkpoint inhibitor therapy in advanced lung cancer.
    Wang C; Li J; Zhang Q; Wu J; Xiao Y; Song L; Gong H; Li Y
    BMC Cancer; 2021 Aug; 21(1):968. PubMed ID: 34454455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuron - specific enolase predicts the prognosis in advanced small cell lung cancer patients treated with first-line PD-1/PD-L1 inhibitors.
    Li L; Zhang Z; Hu Y
    Medicine (Baltimore); 2021 Sep; 100(36):e27029. PubMed ID: 34516493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impacts of probiotics on the efficacies of immune checkpoint inhibitors with or without chemotherapy for patients with advanced non-small-cell lung cancer.
    Morita A; Ichihara E; Inoue K; Fujiwara K; Yokoyama T; Harada D; Ando C; Kano H; Oda N; Tamura T; Ochi N; Kawai H; Inoue M; Hara N; Fujimoto N; Ichikawa H; Oze I; Hotta K; Maeda Y; Kiura K
    Int J Cancer; 2024 May; 154(9):1607-1615. PubMed ID: 38196128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of immune checkpoint inhibitors in advanced
    Hu J; Huang D; Wang Y; Li D; Yang X; Fu Y; Du N; Zhao Y; Li X; Ma J; Hu Y
    Front Immunol; 2022; 13():975246. PubMed ID: 36159795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11).
    Kim H; Kim DW; Kim M; Lee Y; Ahn HK; Cho JH; Kim IH; Lee YG; Shin SH; Park SE; Jung J; Kang EJ; Ahn MJ
    Cancer; 2022 Feb; 128(4):778-787. PubMed ID: 34705268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapeutic efficacy analysis of immunotherapy in small cell lung cancer].
    Zhong J; Zheng QW; Zhao J; Wang ZP; Wu MN; Zhuo ML; Wang YY; Li JJ; Yang X; Chen HX; An TT
    Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):771-776. PubMed ID: 32988161
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments.
    Zheng MM; Tu HY; Yang JJ; Zhang XC; Zhou Q; Xu CR; Jiang BY; Yang XN; Yang XR; Deng JY; Yang MY; Xu BF; Chen XM; Li YS; Wu YL
    Eur J Cancer; 2021 Jun; 150():23-30. PubMed ID: 33882375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of PD-1/PD-L1 inhibitors in patients with non-small cell lung cancer and brain metastases: A real-world retrospective study in China.
    Sheng J; Li H; Yu X; Yu S; Chen K; Pan G; Xie M; Li N; Zhou Z; Fan Y
    Thorac Cancer; 2021 Nov; 12(22):3019-3031. PubMed ID: 34596346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or 
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].
    Li H; Qin N; Yu M; Ma L; Wu Y; Zhang H; Zhang X; Li X; Wang J
    Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):161-166. PubMed ID: 33819965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical study and phase II trial of adapting low-dose radiotherapy to immunotherapy in small cell lung cancer.
    Wang H; Yao Z; Kang K; Zhou L; Xiu W; Sun J; Xie C; Yu M; Li Y; Zhang Y; Zheng Y; Lin G; Pan X; Wu Y; Luo R; Wang L; Tang M; Liao S; Zhu J; Zhou X; Zhang X; Xu Y; Liu Y; Peng F; Wang J; Xiang L; Yin L; Deng L; Huang M; Gong Y; Zou B; Wang H; Wu L; Yuan Z; Bi N; Fan M; Xu Y; Tong R; Yi L; Gan L; Xue J; Mo X; Chen C; Na F; Lu Y
    Med; 2024 Oct; 5(10):1237-1254.e9. PubMed ID: 38964333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter, real-world study on effectiveness and safety of first-line modified PD-1 inhibitors with chemotherapy in advanced non-small cell lung cancer (aNSCLC) with drive gene-negative.
    Li T; Chen C; Liu L; Qin J; Qiu L; Wang A; Dong W; Zhang G; Li Y; Zhao L; Zhang F; Hu Y
    Cancer Med; 2024 Feb; 13(3):e7024. PubMed ID: 38400661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective real-world experience of immunotherapy in patients with extensive stage small-cell lung cancer.
    Qiu G; Wang F; Xie X; Liu T; Zeng C; Chen Z; Zhou M; Deng H; Yang Y; Lin X; Xie Z; Sun G; Zhou C; Liu M
    Cancer Med; 2023 Jul; 12(14):14881-14891. PubMed ID: 37462138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of immune checkpoint inhibitors (ICIs) in extensive-stage small cell lung cancer (SCLC).
    Ma X; Wang S; Zhang Y; Wei H; Yu J
    J Cancer Res Clin Oncol; 2021 Feb; 147(2):593-606. PubMed ID: 32852633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of probiotics use on clinical outcomes of immune checkpoint inhibitors therapy in cancer patients.
    Wan L; Wu C; Wu Q; Luo S; Liu J; Xie X
    Cancer Med; 2023 Jan; 12(2):1841-1849. PubMed ID: 35770869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma.
    Sun M; Ji H; Xu N; Jiang P; Qu T; Li Y
    BMC Cancer; 2022 Jul; 22(1):762. PubMed ID: 35831785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.